Introduction {#tca13055-sec-0005}
============

Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related mortality worldwide.[1](#tca13055-bib-0001){ref-type="ref"} Patients with NSCLC often have distant metastases at the time of diagnosis. Systemic chemotherapy is the standard treatment for patients with advanced NSCLC and includes cytotoxic chemotherapy, molecular targeted therapy (such as EGFR and ALK tyrosine kinase inhibitors \[TKIs\]), and immune checkpoint inhibitors (ICIs, such as PD‐1 and PD‐L1 inhibitors).

Among the ICIs, pembrolizumab is used as first‐line therapy in patients with advanced NSCLC with a PD‐L1 tumor proportion score (TPS) of ≥ 50%.[2](#tca13055-bib-0002){ref-type="ref"} Nivolumab (regardless of PD‐L1 TPS) and pembrolizumab (PD‐L1 TPS ≥ 1%) are used as second‐line or subsequent therapy following cytotoxic chemotherapy.[3](#tca13055-bib-0003){ref-type="ref"}, [4](#tca13055-bib-0004){ref-type="ref"}, [5](#tca13055-bib-0005){ref-type="ref"} Single‐agent chemotherapy (such as docetaxel with or without ramucirumab, or S‐1) is administered in clinical practice after progression in patients who have received ICIs and platinum‐doublet chemotherapy.

The administration of single‐agent chemotherapy as second‐line or subsequent treatment for patients with advanced NSCLC generally results in a poor treatment outcome. In a recent phase 3 study, the objective response rate (ORR), median progression‐free survival (PFS), and median overall survival (OS) in patients administered docetaxel plus ramucirumab were 23--28.9%, 4.5--5.22 months, and 10.5--15.15 months, respectively;[6](#tca13055-bib-0006){ref-type="ref"}, [7](#tca13055-bib-0007){ref-type="ref"} in patients administered docetaxel were 9.9--18.5%, 2.89--4.21 months, and 9.1--14.65 months, respectively;[6](#tca13055-bib-0006){ref-type="ref"}, [7](#tca13055-bib-0007){ref-type="ref"}, [8](#tca13055-bib-0008){ref-type="ref"} and in patients administered S‐1 were 8.3%, 2.86 months, and 12.75 months, respectively.[8](#tca13055-bib-0008){ref-type="ref"}

Recently, it has been suggested that the efficacy of chemotherapy involves not only direct cytotoxic effects, but also activation of tumor‐targeting immune responses.[9](#tca13055-bib-0009){ref-type="ref"} In a phase 2 study, a combination of pembrolizumab, carboplatin, and pemetrexed was suggested as an effective first‐line treatment for patients with advanced non‐squamous NSCLC.[10](#tca13055-bib-0010){ref-type="ref"}

Moreover, an increased number of activated T cells induced by exposure to ICIs may enhance subsequent chemotherapy administered after ICI treatment. Several reports have indicated that subsequent cytotoxic chemotherapy among patients who have received ICIs might have relatively better efficacy.[11](#tca13055-bib-0011){ref-type="ref"}, [12](#tca13055-bib-0012){ref-type="ref"}, [13](#tca13055-bib-0013){ref-type="ref"}, [14](#tca13055-bib-0014){ref-type="ref"} However, two of these studies did not report control data. Other studies have compared results with a small number of control data of non‐platinum cytotoxic chemotherapies without ICIs administered during the same term, but selection bias may have existed because the data were collected in a non‐consecutive manner.

The purpose of the present study was to investigate the efficacy of subsequent cytotoxic chemotherapy after nivolumab compared to the same regimen without pretreatment with ICIs in patients with advanced non‐small cell lung cancer.

Methods {#tca13055-sec-0006}
=======

Data collection {#tca13055-sec-0007}
---------------

The clinical data of advanced NSCLC patients treated with nivolumab during clinical practice at the National Cancer Center Hospital between 17 December 2015 and 31 August 2017 were consecutively reviewed (nivolumab was approved in Japan on 17 December 2015), and the treatment outcomes of docetaxel‐based chemotherapy (docetaxel +/− ramucirumab) or S‐1 after nivolumab administration were analyzed (nivolumab‐treated group). We then compared these results with those of advanced NSCLC patients treated with docetaxel or S‐1 during clinical practice between 17 December 2014 and 16 December 2015 (i.e. in the last year prior to nivolumab approval) who had not previously received ICIs (ICI‐untreated group). None of the patients received docetaxel plus ramucirumab without ICIs because ramucirumab was approved in Japan on 20 June 2016.

Information on gender, histology, driver oncogenes, tumor node metastasis (TNM) staging (Union for International Cancer Control 7th edition TNM classification for lung cancer), age, Eastern Cooperative Oncology Group performance status (ECOG PS), treatment line, and chemotherapy regimen were collected.

All NSCLC histologies, except for carcinoid or sarcomatoid carcinoma, double cancer, NSCLC containing a small cell component, and NSCLC that had transformed to small cell cancer, were eligible for inclusion. Patients who had received molecular targeted therapy, chemoradiotherapy, or the re‐administration of previously administered agents as subsequent treatments were excluded from analysis.

The ORR, disease control rate (DCR), PFS, and follow‐up duration of patients administered cytotoxic chemotherapies were assessed as of 31 December 2017.

The institutional review board of the National Cancer Center Hospital approved this study.

Statistical analysis {#tca13055-sec-0008}
--------------------

ORRs and DCRs were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients who could not be assessed using RECIST version 1.1 were excluded from ORR and DCR analyses. PFS was measured from the date of initial treatment until death before progression, the date of disease progression, or the date of clinical progression. The follow‐up period was measured from the date of initial treatment until the data cutoff date of 31 December 2017, or until patients were lost to follow‐up. All patients were included in PFS and follow‐up period analyses.

The PFS and the follow‐up period were estimated using the Kaplan--Meier method. Odds ratios (ORs) were assessed with the use of a nominal logistic regression model, and hazard ratios (HRs) were assessed with the use of a Cox proportional hazards model. All statistical analyses were performed using JMP version 13.1.0.

Results {#tca13055-sec-0009}
=======

Patients {#tca13055-sec-0010}
--------

### Nivolumab‐treated group {#tca13055-sec-0011}

A total of 230 patients with NSCLC were treated with nivolumab during clinical practice at the National Cancer Center Hospital between 17 December 2015 and 31 August 2017. Eight patients were excluded because of a particular histology (1 carcinoid tumor, 4 sarcomatoid carcinomas, 1 double cancer, 1 NSCLC containing a small cell component, and 1 NSCLC that had transformed to small cell cancer). In total, 163 patients discontinued nivolumab treatment because of disease progression.

Fifty‐four patients were administered cytotoxic chemotherapy (any line of treatment) after receiving nivolumab. Thirty patients were administered docetaxel‐based chemotherapy and 21 patients were administered S‐1. Twenty‐two patients who received docetaxel‐based chemotherapy and 15 patients who received S‐1 were evaluable using RECIST.

Fifty patients were administered subsequent cytotoxic chemotherapy immediately following nivolumab. Twenty‐four patients were administered docetaxel‐based chemotherapy and 15 patients were administered S‐1. Eighteen patients who received docetaxel‐based chemotherapy and 10 patients who received S‐1 were evaluable using RECIST (Fig [1](#tca13055-fig-0001){ref-type="fig"}a).

![Flow diagram: patients administered (**a**) cytotoxic chemotherapy after nivolumab, (**b**) docetaxel without immune checkpoint inhibitors (ICIs), and (**c**) S‐1 without ICIs. BSC, best**‐**supportive care; DTX, docetaxel; NSCLC, non‐small cell lung cancer; Ram, ramucirumab.](TCA-10-1141-g001){#tca13055-fig-0001}

### Immune checkpoint inhibitor‐untreated group {#tca13055-sec-0012}

Overall, 81 patients with NSCLC were treated with docetaxel during clinical practice between 17 December 2014 and 16 December 2015. Three patients were excluded because of a particular histology (2 sarcomatoid carcinomas and 1 double cancer). Five patients who had previously been treated with ICIs and seven patients who had received docetaxel as a trial therapy were also excluded. In total, 66 patients who received docetaxel without ICIs were analyzed. Fifty patients administered docetaxel‐based chemotherapy were evaluable using RECIST (Fig [1](#tca13055-fig-0001){ref-type="fig"}b).

Twenty‐nine patients with NSCLC were treated with S‐1 during clinical practice between 17 December 2014 and 16 December 2015. One patient with double cancer was excluded. Four patients who had been previously treated with ICIs and one patient who had received S‐1 as a re‐challenge therapy were also excluded. In total, 23 patients who received S‐1 without ICIs were analyzed. Seventeen patients who received S‐1 were evaluable using RECIST (Fig [1](#tca13055-fig-0001){ref-type="fig"}c).

Patient characteristics at the time of cytotoxic chemotherapy {#tca13055-sec-0013}
-------------------------------------------------------------

In general, the patient characteristics were similar among the groups (docetaxel‐based chemotherapy immediately after nivolumab, S‐1 immediately after nivolumab, any line of docetaxel‐based chemotherapy after nivolumab, any line of S‐1 after nivolumab, docetaxel without ICIs, and S‐1 without ICIs), although more women than men received S‐1 immediately after nivolumab (Table [1](#tca13055-tbl-0001){ref-type="table"}).

###### 

Patient characteristics at the time of cytotoxic chemotherapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                   DTX‐based CT immediately after Nivo   S‐1 immediately after Nivo   DTX‐based CT in any line after Nivo   S‐1 in any line after Nivo   DTX without ICIs   S‐1 without ICIs
  ---------------------------------------------------------------- ------------------------------------- ---------------------------- ------------------------------------- ---------------------------- ------------------ ------------------
  N                                                                24                                    15                           30                                    21                           66                 23

  Gender                                                                                                                                                                                                                    

  Male                                                             13 (54.2%)                            5 (33.3%)                    16 (53.3%)                            11 (52.4%)                   52 (78.8%)         15 (65.2%)

  Female                                                           11 (45.8%)                            10 (66.7%)                   14 (46.7%)                            10 (47.6%)                   14 (21.2%)         8 (34.8%)

  Age, median (range)                                              64 (39--76)                           60 (42--77)                  63 (39--76)                           60 (42--77)                  63 (35--82)        62 (35--73)

  ECOG PS                                                                                                                                                                                                                   

  0/1                                                              22 (91.7%)                            13 (86.7%)                   25 (83.3%)                            19 (90.5%)                   61 (92.4%)         20 (87.0%)

  2                                                                2 (8.3%)                              2 (13.3%)                                                          2 (9.5%)                     5 (7.6%)           1 (4.3%)

  NA                                                               0                                     0                            5 (16.7%)\                            0                            0                  2 (8.7%)
                                                                                                                                      0                                                                                     

  Histology                                                                                                                                                                                                                 

  Ad                                                               17 (70.8%)                            12 (80.0%)                   23 (76.7%)                            17 (81.0%)                   51 (77.3%)         14 (60.9%)

  Sq                                                               6 (25.0%)                             3 (20.0%)                    6 (20.0%)                             4 (19.0%)                    13 (19.7%)         9 (39.1%)

  LCNEC                                                            0                                     0                            0                                     0                            2 (3.0%)           0

  NSCLC, NOS                                                       1 (4.2%)                              0                            1 (3.3%)                              0                            0                  0

  Driver oncogenes                                                                                                                                                                                                          

  *EGFR* mutation                                                  5 (20.8%)                             2 (13.3%)                    8 (26.7%)                             4 (19.0%)                    13 (19.7%)         2 (8.7%)

  *ALK* rearrangement                                              0                                     0                            1 (3.3%)                              0                            4 (6.1%)           0

  TNM staging (at diagnosis)                                                                                                                                                                                                

  IA/IB                                                            3 (12.5%)                             0                            4 (13.3%)                             2 (9.5%)                     3 (4.5%)           2 (8.7%)

  IIA/IIB                                                          0                                     3 (20.0%)                    1 (3.3%)                              4 (19.0%)                    10 (15.2%)         3 (13.0%)

  IIIA/B                                                           4 (16.7%)                             5 (33.3%)                    6 (20.0%)                             5 (23.8%)                    15 (22.7%)         3 (13.0%)

  IVA/B                                                            17 (70.8%)                            7 (46.7%)                    19 (63.3%)                            10 (47.6%)                   38 (57.6%)         15 (65.2%)

  Treatment line                                                                                                                                                                                                            

  1                                                                0                                     0                            0                                     0                            6 (9.1%)           0

  2                                                                0                                     1 (6.7%)                     0                                     1 (4.8%)                     36 (54.5%)         7 (30.4%)

  3                                                                18 (75.0%)                            9 (60.0%)                    18 (60.0%)                            9 (42.9%)                    14 (21.2%)         9 (39.1%)

  4                                                                3 (12.5%)                             3 (20.0%)                    5 (16.7%)                             5 (23.8%)                    7 (10.6%)          6 (26.1%)

  5                                                                1 (4.2%)                              1 (6.7%)                     1 (3.3%)                              2 (9.5%)                     2 (3.0%)           0

  6                                                                2 (8.3%)                              0                            3 (10.0%)                             0                            0                  0

  7                                                                0                                     0                            2 (6.6%)                              1 (4.8%)                     1 (1.5%)           1 (4.3%)

  8                                                                0                                     1 (6.7%)                     0                                     2 (9.5%)                     0                  0

  9                                                                0                                     0                            1 (3.3%)                              0                            0                  0

  10                                                               0                                     0                            0                                     0                            0                  0

  11                                                               0                                     0                            0                                     1 (4.8%)                     0                  0

  Regimen                                                                                                                                                                                                                   

  DTX‐based                                                                                                                                                                                                                 

  DTX                                                              6 (25.0%)                             ---                          10 (33.3%)                            ---                          66 (100%)          ---

  DTX + Ram                                                        18 (75.0%)                            ---                          20 (66.7%)                            ---                          ---                ---

  S‐1                                                              ---                                   15 (100%)                    ---                                   21 (100%)                    ---                23 (100%)

  Interval from the last infusion of Nivo, median months (range)   0.9 (0.5--12.7)                       1.3 (0.5--3.0)               1.2 (0.5--15.5)                       1.4 (0.5--9.1)               ---                ---
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ad, adenocarcinoma; CBDCA, carboplatin; CT, chemotherapy; DTX, docetaxel; ECOG PS, Eastern Cooperative Oncology Group performance status; ETP, etoposide; GEM, gemcitabine; ICIs, immune checkpoint inhibitors; LCNEC, large‐cell neuroendocrine carcinoma; NA, not analyzed; Nivo, nivolumab; NOS, not otherwise specified; NSCLC, non‐small cell lung cancer; PEM, pemetrexed; Ram, ramucirumab; Sq, squamous‐cell carcinoma; TNM, tumor node metastasis.

Efficacy {#tca13055-sec-0014}
--------

### Objective response and disease control rates {#tca13055-sec-0015}

While the ORR to docetaxel without ICIs was 16.0% (8/50), the ORRs to docetaxel‐based chemotherapy immediately after nivolumab and in any line after nivolumab were 27.8% (5/18, OR 2.02, 95% confidence interval \[CI\] 0.56--7.25; *P* = 0.28) and 27.3% (6/22, OR 1.97, 95% CI 0.59--6.57; *P* = 0.27), respectively. The ORR to S‐1 without ICIs was 17.6% (3/17), and the ORRs to S‐1 immediately after nivolumab and in any line after nivolumab were 30.0% (3/10, OR 2.00, 95% CI 0.32--12.59; *P* = 0.46) and 20.0% (3/15, OR 1.17, 95% CI 0.20--6.89; *P* = 0.86), respectively. The ORR to docetaxel or S‐1 without ICIs was 16.4% (11/67), and the ORRs to docetaxel‐based chemotherapy or S‐1 immediately after nivolumab and in any line after nivolumab were 28.6% (8/28, OR 2.04, 95% CI 0.72--5.78; *P* = 0.18) and 24.3% (9/37, OR 1.64, 95% CI 0.61--4.41; *P* = 0.33), respectively.

In addition, we analyzed the DCRs. The DCR to docetaxel without ICIs was 56.0% (28/50), and the DCRs to docetaxel‐based chemotherapy immediately after nivolumab and in any line after nivolumab were 55.6% (10/18, OR 0.98, 95% CI 0.33--2.91; *P* = 0.97) and 54.5% (12/22, OR 0.94, 95% CI 0.34--2.58; *P* = 0.91), respectively. The DCR to S‐1 without ICIs was 58.8% (10/17), and the DCRs to S‐1 immediately after nivolumab and in any line after nivolumab were 50.0% (5/10, OR 0.70, 95% CI 0.15--3.37; *P* = 0.66) and 46.7% (7/15, OR 0.61, 95% CI 0.15--2.49; *P* = 0.49), respectively. The DCR to docetaxel or S‐1 without ICIs was 56.7% (38/67), and the DCRs to docetaxel‐based chemotherapy or S‐1 immediately after nivolumab and in any line after nivolumab were 53.6% (15/28, OR 0.88, 95% CI 0.36--2.14; *P* = 0.78) and 51.4% (19/37, OR 0.81; 95% CI 0.36--1.80; *P* = 0.60), respectively (Table [2](#tca13055-tbl-0002){ref-type="table"}).

###### 

Responses and progression‐free survival of patients administered cytotoxic chemotherapy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Response              DTX‐based CT immediately after Nivo   S‐1 immediately after Nivo   DTX‐based CT or S‐1 immediately after Nivo   DTX‐based CT in any line after Nivo   S‐1 in any line after Nivo   DTX‐based CT or S‐1 in any line after Nivo   DTX without ICIs   S‐1 without ICIs   DTX or S‐1 without ICIs
  --------------------- ------------------------------------- ---------------------------- -------------------------------------------- ------------------------------------- ---------------------------- -------------------------------------------- ------------------ ------------------ -------------------------
  N                     24                                    15                           39                                           30                                    21                           51                                           66                 23                 89

  Evaluable by RECIST   18                                    10                           28                                           22                                    15                           37                                           50                 17                 67

  CR                    0                                     0                            0                                            0                                     0                            0                                            0                  0                  0

  PR                    5                                     3                            8                                            6                                     3                            9                                            8                  3                  11

  SD                    5                                     2                            7                                            6                                     4                            10                                           20                 7                  27

  PD                    8                                     5                            13                                           10                                    8                            18                                           22                 7                  29

  NE                    6                                     5                            11                                           8                                     6                            14                                           16                 6                  22

  ORR (%)               27.8                                  30.0                         28.6                                         27.3                                  20.0                         24.3                                         16.0               17.6               16.4

  DCR (%)               55.6                                  50.0                         53.6                                         54.5                                  46.7                         51.4                                         56.0               58.8               56.7

  Median PFS\           5.98                                  3.88                         5.26                                         4.67                                  3.06                         3.88                                         2.87               2.63               2.74
  (months)                                                                                                                                                                                                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CR, complete response; CT, chemotherapy; DCR, disease control rate; DTX, docetaxel; ICIs, immune checkpoint inhibitors; NE, not evaluable; Nivo, nivolumab; ORR, objective response rate; PD, progressive disease; PFS, progression‐free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD stable disease.

We observed a tendency toward an objective response to chemotherapy after nivolumab; however, the difference was not significant because of the small sample size. No significant difference in the DCR between chemotherapy after nivolumab and without ICIs was observed.

### Progression‐free survival {#tca13055-sec-0016}

While the median PFS for docetaxel without ICIs was 2.87 months, the median PFS rates for docetaxel‐based chemotherapy immediately after nivolumab and in any line after nivolumab were 5.98 months (HR 0.69, 95% CI 0.35--1.26; *P* = 0.23) and 4.67 months (HR 0.76, 95% CI 0.41--1.32; *P* = 0.34), respectively. The median PFS to S‐1 without ICIs was 2.63 months, and the median PFS rates to S‐1 immediately after nivolumab and in any line after nivolumab were 3.88 months (HR 1.00, 95% CI 0.40--2.38; *P* = 1.00) and 3.06 months (HR 0.81, 95% CI 0.36--1.81; *P* = 0.60), respectively. The median PFS to docetaxel or S‐1 without ICIs was 2.74 months, and the median PFS rates to docetaxel‐based chemotherapy or S‐1 immediately after nivolumab and in any line after nivolumab were 5.26 months (HR 0.79, 95% CI 0.47--1.29; *P* = 0.36) and 3.88 months (HR 0.92, 95% CI 0.58--1.43; *P* = 0.72), respectively (Table [2](#tca13055-tbl-0002){ref-type="table"}, Fig [2](#tca13055-fig-0002){ref-type="fig"}).

![Kaplan--Meier curve of progression‐free survival (PFS). CI, confidence interval; CT, chemotherapy; DTX, docetaxel; ICIs, immune checkpoint inhibitors; Nivo, nivolumab.](TCA-10-1141-g002){#tca13055-fig-0002}

We observed a positive tendency in PFS of chemotherapy after nivolumab; however, the difference was not significant because of the small sample size.

### Subgroup analyses {#tca13055-sec-0017}

We analyzed subgroups of chemotherapies by treatment lines and subgroups of docetaxel monotherapy after nivolumab. Subgroup analyses of chemotherapies by treatment line demonstrated similar trends, but subgroup analyses of docetaxel monotherapy showed no difference after nivolumab. The details are shown in Table [3](#tca13055-tbl-0003){ref-type="table"}.

###### 

Subgroup analyses of responses and progression‐free survival of patients administered cytotoxic chemotherapy

  Response              DTX immediately after Nivo   DTX in any line after Nivo   DTX‐based CT in third‐line immediately after Nivo   S‐1 in second or third‐line immediately after Nivo   DTX‐based CT or S‐1 in second or third‐line immediately after Nivo   DTX in first or second‐line without ICIs   S‐1 in second‐line without ICIs   DTX or S‐1 in first or second‐line without ICIs
  --------------------- ---------------------------- ---------------------------- --------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------ --------------------------------- -------------------------------------------------
  N                     6                            10                           18                                                  10                                                   28                                                                   42                                         7                                 49
  Evaluable by RECIST   3                            5                            14                                                  8                                                    22                                                                   32                                         6                                 38
  CR                    0                            0                            0                                                   0                                                    0                                                                    0                                          0                                 0
  PR                    0                            0                            4                                                   2                                                    6                                                                    4                                          1                                 5
  SD                    1                            1                            5                                                   1                                                    6                                                                    17                                         2                                 19
  PD                    2                            4                            5                                                   5                                                    10                                                                   11                                         3                                 14
  NE                    3                            5                            4                                                   2                                                    6                                                                    10                                         1                                 11
  ORR (%)               0                            0                            28.6                                                25.0                                                 27.3                                                                 12.5                                       16.7                              13.2
  DCR (%)               33.3                         20.0                         64.3                                                37.5                                                 54.5                                                                 65.6                                       50.0                              63.2
  Median PFS (months)   1.61                         1.61                         6.44                                                3.88                                                 5.26                                                                 3.66                                       1.32                              3.20

CR, complete response; CT, chemotherapy; DCR, disease control rate; DTX, docetaxel; ICIs, immune checkpoint inhibitors; NE, not evaluable; Nivo, nivolumab; ORR, objective response rate; PD, progressive disease; PFS, progression‐free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

Follow‐up period {#tca13055-sec-0018}
----------------

The percentages of patients evaluated after three and six‐month follow‐up periods and the median follow‐up period after docetaxel or S‐1 without ICIs were 97.7%, 97.7%, and not evaluable, respectively, while those after docetaxel‐based chemotherapy or S‐1 in any line after nivolumab were 98.0%, 80.9%, and 8.35 months, respectively.

Discussion {#tca13055-sec-0019}
==========

We assessed the efficacy of subsequent cytotoxic chemotherapy among patients with advanced NSCLC. The ORR, DCR, and median PFS of patients administered docetaxel‐based chemotherapy or S‐1 after nivolumab, especially immediately after nivolumab, tended to be better than those of patients administered docetaxel or S‐1 without ICIs.

A previous preclinical study demonstrated that nivolumab enhances T cell proliferation and cytokine production in vitro,[15](#tca13055-bib-0015){ref-type="ref"} while another study reported that the addition of nonspecifically activated CD4^+^ T cells as a chemosensitizer greatly enhanced the cytotoxic effect of chemotherapy in both in vitro and in vivo human tumor models.[16](#tca13055-bib-0016){ref-type="ref"}

Several retrospective clinical studies have also reported that subsequent cytotoxic chemotherapy after ICI treatment may have better efficacy (Table [4](#tca13055-tbl-0004){ref-type="table"}).[11](#tca13055-bib-0011){ref-type="ref"}, [12](#tca13055-bib-0012){ref-type="ref"}, [13](#tca13055-bib-0013){ref-type="ref"}, [14](#tca13055-bib-0014){ref-type="ref"} The reported ORRs, DCRs, and median PFS periods were 26.9--53.4%, 48.5--77.6%, and 2.5--4.7 months, respectively. However, these studies might have contained some biases. Grigg[11](#tca13055-bib-0011){ref-type="ref"} and Schvartsman *et al.* [13](#tca13055-bib-0013){ref-type="ref"} did not analyze the patients who were not treated with ICIs, while Leger[12](#tca13055-bib-0012){ref-type="ref"} compared patients treated with and without ICIs during the same term. Park *et al.* compared the efficacy of chemotherapy immediately before and after ICIs in the same patients.[14](#tca13055-bib-0014){ref-type="ref"} However, selection bias may have existed because these data were collected in a non‐consecutive manner. To overcome this bias, we consecutively reviewed patients treated with nivolumab during clinical practice and compared the results with those of patients who had not received ICIs before the approval of nivolumab.

###### 

Recent studies of cytotoxic chemotherapy after ICIs

  Study                                                           N    ORR (%)   DCR (%)   Median PFS (months)
  --------------------------------------------------------------- ---- --------- --------- ---------------------
  Grigg[11](#tca13055-bib-0011){ref-type="ref"}                                            
  CT following ICIs                                               39   30.8      53.8      2.5
  No prior CT                                                     6    50.0      83.3      NA
  ≧1 prior CT                                                     33   27.3      48.5      NA
  Leger[12](#tca13055-bib-0012){ref-type="ref"}                                            
  CT following ICIs                                               67   26.9      77.6      NA
  CT without ICIs                                                 15   6.7       60.0      NA
  Schvartsman *et al.* [13](#tca13055-bib-0013){ref-type="ref"}                            
  Single agent CT following ICIs                                  28   39.3      71.4      4.7
  Park *et al.* [14](#tca13055-bib-0014){ref-type="ref"}                                   
  Last CT before ICIs                                             63   34.9      NA        4.7
  Non‐platinum                                                    20   25.0      NA        3.5
  CT immediately after ICIs                                       73   53.4      NA        4.5
  Non‐platinum                                                    49   46.9      NA        3.8
  Present study                                                                            
  DTX‐based CT or S‐1 immediately after Nivo                      39   28.6      53.6      5.26
  DTX‐based CT or S‐1 in any line after Nivo                      51   24.3      51.4      3.88
  DTX or S‐1 without ICIs                                         89   16.4      56.7      2.74

CT, cytotoxic chemotherapy; DTX, docetaxel; ICIs, immune checkpoint inhibitors; NA, not analyzed; Nivo, nivolumab; PFS, progression‐free survival.

Subsequent docetaxel‐based chemotherapy or S‐1 immediately after nivolumab demonstrated slightly better treatment efficacy, compared to that observed in patients not pretreated with ICIs. The ORR and median PFS of patients administered docetaxel‐based chemotherapy after nivolumab were better than those administered docetaxel without ICIs. Additionally, the ORR and the median PFS of the patients who received S‐1 immediately after nivolumab were better than those who received S‐1 without ICIs. However docetaxel monotherapy after nivolumab showed no difference; we consider some confounding factors, such as small sample size and the selection of patients unable to receive ramucirumab in combination with docetaxel, responsible for this result. Although the addition of ramucirumab to docetaxel might have led to better efficacy, the similar result of S‐1 treatment after nivolumab cannot be explained in this manner because S‐1 was used as single‐agent chemotherapy.

The treatment efficacy of cytotoxic chemotherapy after nivolumab might increase when it is administered immediately after nivolumab. The number of activated T cells induced by exposure to nivolumab might decrease with time, or the response to nivolumab might continue for a while after progression. It may be desirable to use ICIs early during the treatment of advanced NSCLC and to administer subsequent treatments as soon as possible once the ICIs have been discontinued.

The present study had some limitations. First, we could not analyze the PD‐L1 TPS because nivolumab can be administered regardless of the PD‐L1 TPS. Whether the expression of PD‐L1 is correlated with the efficacy of a chemosensitizer remains uncertain. Second, this study included patients administered chemotherapy at various treatment lines. Third, a few of the patients were administered docetaxel monotherapy without ramucirumab after nivolumab because combination therapy with docetaxel and ramucirumab has only recently become standard therapy.

In conclusion, subsequent cytotoxic chemotherapy, especially immediately after nivolumab treatment, demonstrated better treatment efficacy than that of regimens without ICI pretreatment.
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